SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001640334-22-000990
Filing Date
2022-05-13
Accepted
2022-05-13 17:14:15
Documents
48
Period of Report
2022-03-31

Document Format Files

Seq Description Document Type Size
1 FORM 6-K nymox_6k.htm   iXBRL 6-K 38986
2 EX-99.1 nymox_ex991.htm   iXBRL EX-99.1 370624
3 EX-99.2 nymox_ex992.htm EX-99.2 18709
4 EX-99.3 nymox_ex993.htm EX-99.3 18746
10 nymox_ex991img1.jpg GRAPHIC 5630
  Complete submission text file 0001640334-22-000990.txt   1980880

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA nymox-20220331.xsd EX-101.SCH 39852
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE nymox-20220331_lab.xml EX-101.LAB 139133
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE nymox-20220331_cal.xml EX-101.CAL 19339
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nymox-20220331_pre.xml EX-101.PRE 118463
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE nymox-20220331_def.xml EX-101.DEF 57740
42 EXTRACTED XBRL INSTANCE DOCUMENT nymox_6k_htm.xml XML 267812
Mailing Address 9900 CAVENDISH BLVD., SUITE 306 ST. LAURENT QUEBEC CANADA A8 H4M 2V2
Business Address 9900 CAVENDISH BLVD., SUITE 306 ST. LAURENT QUEBEC CANADA A8 H4M 2V2 1-800-936-9669
NYMOX PHARMACEUTICAL CORP (Filer) CIK: 0001018735 (see all company filings)

IRS No.: 000000000 | Fiscal Year End: 1231
Type: 6-K | Act: 34 | File No.: 001-12033 | Film No.: 22923987
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
Office of Life Sciences